Bristol Myers Squibb (BMS) has successfully defended itself against a high-profile antitrust lawsuit that accused the pharmaceutical giant of engaging in intellectual property (IP) fraud to delay generic competition for its cancer drug, Pomalyst. A federal judge dismissed the suit, ruling there was insufficient evidence to prove the company had manipulated the patent system to maintain its market monopoly.
The case, brought by a group of drug purchasers, alleged that Bristol Myers had fraudulently obtained patents to unlawfully extend its exclusivity over Pomalyst, thereby inflating prices and harming competition. However, U.S. District Judge Richard J. Leon ruled that the plaintiffs failed to demonstrate the necessary intent or misrepresentation to constitute IP fraud.
Background of the Lawsuit
Pomalyst, a treatment for multiple myeloma, has been a key revenue driver for Bristol Myers. Since its approval by the U.S. Food and Drug Administration (FDA) in 2013, it has generated billions in sales annually. The plaintiffs in the case argued that BMS had filed “sham patents” to block generic drugmakers from entering the market, violating antitrust laws in the process.
At the center of the case were claims that BMS had knowingly misrepresented scientific data and drug development timelines during its patent application process, thereby deceiving the U.S. Patent and Trademark Office (USPTO).
Court’s Decision
Judge Leon found that while the plaintiffs made sweeping claims, they lacked the concrete evidence required to establish that Bristol Myers committed “Walker Process” fraud—a rare but serious type of legal violation involving the use of a fraudulently obtained patent to stifle competition.
“Mere disagreement with the strength or novelty of a patent is not enough to constitute fraud,” Judge Leon wrote in the decision. He emphasized that the plaintiffs could not show that BMS had intentionally misled the USPTO or that the agency would have rejected the patents had it known the full context.
The court’s dismissal of the case underscores the high legal threshold required to prove IP-related antitrust violations and protects the standard practices surrounding patent filings in the pharmaceutical industry.
Industry Implications
The ruling is a significant victory not just for Bristol Myers but for the broader pharmaceutical sector, which often faces scrutiny over practices perceived to delay generic drug competition. Patent strategies, including evergreening and secondary patents, have been criticized by consumer advocacy groups, but courts have generally upheld them unless clear evidence of fraud or misconduct is shown.
Legal experts note that while the case drew attention due to the high cost of Pomalyst and its role in Bristol Myers’ product lineup, it ultimately did not meet the legal standards for overturning a patent based on fraud.
“This decision reaffirms the principle that patent disputes must be resolved with clear and convincing evidence of wrongdoing—not just frustration over drug pricing,” said Karen Li, a pharmaceutical IP attorney based in New York.
What’s Next?
Although the current lawsuit has been dismissed, generic manufacturers and advocacy groups may still pursue regulatory or legislative avenues to increase access to more affordable alternatives. Meanwhile, BMS continues to market Pomalyst globally and remains a major player in the oncology space.
The plaintiffs have not yet indicated whether they will appeal the ruling.
Pomalyst’s Market Standing
Pomalyst remains under patent protection in the U.S. until 2026, with additional protections in other jurisdictions. In 2024, the drug accounted for approximately $2.9 billion in global sales, according to company filings.
For Bristol Myers, the lawsuit’s dismissal helps safeguard a lucrative revenue stream while reinforcing confidence in its IP portfolio amid rising legal and political pressures over drug affordability.
